European Pharmaceutical Review
MAY 7, 2024
percent compound annual growth rate (CAGR) between 2024 to 2029. billion by 2029. by 2029 appeared first on European Pharmaceutical Review. A new report by MarketsandMarkets has predicted that the injectable drug delivery market will reach an 8.6 The market is anticipated to value $1139.4 Eli Lilly and Company and Sandoz.
Express Pharma
JANUARY 4, 2024
billion by 2029 across the eight major markets (8MM*) at a compound annual growth rate (CAGR) of 7.4 billion in 2029.” million by 2029. bn by 2029 driven by novel drug launches: GlobalData appeared first on Express Pharma. The major depressive disorder (MDD) market is forecast to grow from $4.7
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
MARCH 15, 2024
per cent compound annual growth rate (CAGR) from 2023 to 2029, reaching a substantial market size of $105 billion in 2029. per cent CAGR and a market size of $51 billion in 2029, nearly half of the GLP1 agonist market. billion annually by 2029.
Express Pharma
FEBRUARY 5, 2024
The deal includes promising compounds undergoing Phase II trials for malignancies and access to the Tri-specific T cell Activating Construct (TriTAC) platform, positioning the US-based pharma giant for significant advancements in therapeutic innovation. The clinical results demonstrated good objective response rates in patients.
Express Pharma
NOVEMBER 16, 2023
The global cell and gene therapy market is expected to reach $80 billion in 2029, with a high compound annual growth rate of 51.6 per cent between 2023 and 2029, according to GlobalData forecasts. The US FDA is currently considering approval of Casgevy for SCA.
Express Pharma
SEPTEMBER 19, 2023
billion by 2029 at a compounded annual growth rate (CAGR) of 8.2 The high prevalence of breast cancer, ovarian cancer, pancreatic cancer and cancers of the lung and intestine is a key driver of the global oncology market, which was valued at $286.04 billion in 2021 and is projected to reach $536.01 per cent from 2021 to 2030.
Pharmaceutical Technology
APRIL 28, 2023
In 2022, US sales of Ozempic contributed to 65% of global sales; this is expected to continue, with the US market forecast to continue capturing the majority of sales, generating $71bn between 2023–2029. It is forecast that Ozempic will sustain its sales growth over the next five years, with an expected annual sales figure of $17bn in 2029.
Expert insights. Personalized for you.
69 
Let's personalize your content